Sangamo Therapeutics, Inc.
LSE: 0R1D.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Alexander D. Macrae Ch.B
- Employees
- 183
- Headquarters
- Richmond, United States
- IPO year
- 2014
- Market cap
- $49.1M
- Website
- https://www.sangamo.com
Loading 0R1D…
Loading profile data…Frequently asked questions about 0R1D
What does Sangamo Therapeutics, Inc. (0R1D.L) do?
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucle...
Where does 0R1D.L trade?
Sangamo Therapeutics, Inc. (0R1D.L) trades on the London Stock Exchange.
What sector is 0R1D.L in?
Sangamo Therapeutics, Inc. (0R1D.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Sangamo Therapeutics, Inc.?
Alexander D. Macrae Ch.B is the chief executive officer of Sangamo Therapeutics, Inc. (0R1D.L).
Where is Sangamo Therapeutics, Inc. headquartered?
Sangamo Therapeutics, Inc. is headquartered in United States.
Does 0R1D.L pay a dividend?
Sangamo Therapeutics, Inc. (0R1D.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0R1D.L go public?
Sangamo Therapeutics, Inc. (0R1D.L) completed its initial public offering in 2014.